- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03364764
Sirolimus Treatment for Refractory PRCA
Sirolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study
Study Overview
Detailed Description
Pure red cell aplasia (PRCA) is a rare normocytic normochromic anemia with reticulocytopenia, characterized by a reduction of erythroid precursors from the bone marrow, could be divided into congenital and acquired PRCA according to pathogenesis. Congenital PRCA, also known as Diamond-Blackfan syndrome, has been associated with pathogenic variant in GATA1 and TSR2 and gene encode ribosomal proteins. Acquired PRCA can be a primary disease which is usually mediated by immunology, or secondary to other diseases, such as lymphoproliferative diseases, autoimmune diseases, thymoma, infection, or drugs. The first line therapy of acquired PRCA is Cyclosporine A and steroids, the second line therapy are anti-CD20, ATG, immunosuppressive drugs like cyclophosphamide, bone marrow transplantation. Unfortunately, some patients did not response or tolerate the above treatments.
Sirolimus (rapamycin) is an agent produced by the bacterium Streptomyces hygroscopicus, inhibits the mammalian target of rapamycin (mTOR). mTOR is a serine/threonine kinase that regulates cell growth, proliferation, metabolism and survival in eukaryotic cells, and is identified as two interacting complex, mTORC1 and mTORC2. Sirolimus primarily inhibits mTORC1, has been approved for prevent organ transplant rejection, especially in renal transplantation, sirolimus also promises to treat autoimmune, degenerative and hyperproliferative disorders. Recently, sirolimus has been reported to be effective and well tolerated for many immune-mediated cytopenias, such as autoimmune lymphoproliferative syndrome, immune thrombocytopenia, EVANS syndrome, etc. However, due to the rare occurrence of PRCA and good response rate to cyclosporine, there are very few studies of sirolimus on refractory PRCA so far.
In this study, It is anticipate to evaluate the effect of sirolimus on 30 patients with refractory PRCA, the side-effects was documented and plasma concentration of sirolimus will be monitor.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Peking Union Medical College Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Refractory pure red cell aplasia.
- Excluding other diseases which might cause hematological abnormalities.
- No response or intolerant to first and second line therapies.
- 18-80 years old.
- All subjects must: agree not to donate blood or be counseled about pregnancy precautions and risks of fetal exposure.
- Written informed consent.
Exclusion Criteria:
- NOT refractory pure red cell anemia.
- Response and well tolerate to first or second line therapy.
- Patients who are under 18-year-old or over 80-year-old.
- Pregnant or lactating.
- Patients unwilling to or unable to comply with the protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: efficiency of sirolimus on PRCA
A prospective research of the sirolimus efficiency on refractory PRCA patients On refractory PRCA patients, sirolimus was tried.
Dosage: 2mg QD for the first day, then 1 mg QD.
Medication time should last at least 6 months.
|
On refractory PRCA patients, sirolimus was tried.
Dosage: 2mg QD for the first day, then 1 mg QD.
Medication time should last at least 6 months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hemoglobin level
Time Frame: 6 months
|
Hemoglobin level in g/L
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hemoglobin level
Time Frame: 2 years
|
Hemoglobin level in g/L
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Bing B Han, PhD., Peking Union Medical College Hospital
Publications and helpful links
General Publications
- Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17-28. doi: 10.1182/blood-2015-07-657981. Epub 2015 Oct 26.
- Li J, Wang Z, Dai L, Cao L, Su J, Zhu M, Yu Z, Bai X, Ruan C. Effects of rapamycin combined with low dose prednisone in patients with chronic immune thrombocytopenia. Clin Dev Immunol. 2013;2013:548085. doi: 10.1155/2013/548085. Epub 2013 Dec 2.
- Means RT Jr. Pure red cell aplasia. Blood. 2016 Nov 24;128(21):2504-2509. doi: 10.1182/blood-2016-05-717140.
- Teachey DT, Greiner R, Seif A, Attiyeh E, Bleesing J, Choi J, Manno C, Rappaport E, Schwabe D, Sheen C, Sullivan KE, Zhuang H, Wechsler DS, Grupp SA. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol. 2009 Apr;145(1):101-6. doi: 10.1111/j.1365-2141.2009.07595.x. Epub 2009 Feb 4.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRCA-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pure Red Cell Aplasia
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedPure Red-cell AplasiaUnited Kingdom, Sweden, South Africa, Brazil, Canada, Germany, Norway, Thailand
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
-
Bing HanCompletedPure Red Cell Aplasia, AcquiredChina
-
Peking Union Medical College HospitalUnknown
-
Institute of Hematology & Blood Diseases Hospital...TerminatedAcquired Pure Red Cell AplasiaChina
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedPure Red-cell AplasiaUnited Kingdom, Sweden, South Africa, Brazil, Norway, France, Thailand
-
Johnson & Johnson Pharmaceutical Research & Development...Janssen-Cilag International NVCompletedChronic Kidney Failure | Pure Red-Cell AplasiaPoland, United Kingdom, Belgium, Germany, Spain, Portugal, Australia, Switzerland, Finland, Greece, Sweden, Netherlands, Norway, Ireland, Denmark
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
University of CalgaryRecruitingSickle Cell Disease | Pure Red Cell Aplasia | Stem Cell Transplant Complications | Red Blood Cell DisorderCanada
-
Peking Union Medical College HospitalUnknownPure Red Cell Aplasia | Autoimmune Hemolytic Anemia | Evans SyndromeChina
Clinical Trials on Sirolimus
-
Aadi Bioscience, Inc.Approved for marketingTSC1 | TSC2 | PEComa, Malignant | mTOR Pathway Abberation
-
Johns Hopkins UniversityMacuSight, Inc.CompletedPanuveitis | Uveitis | Posterior Uveitis | Intermediate UveitisUnited States
-
Aadi Bioscience, Inc.CompletedHigh Grade Recurrent Glioma and Newly Diagnosed GlioblastomaUnited States
-
Stefan Schieke MDWithdrawnCutaneous T-cell Lymphoma (CTCL)United States
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)CompletedLymphangioleiomyomatosisUnited States
-
The University of Texas Health Science Center,...Society for Pediatric DermatologyCompletedTuberous Sclerosis | Neurofibromatoses | Neurofibroma | AngiofibromaUnited States
-
Xijing HospitalAir Force Military Medical University, China; Shanghai MicroPort Medical (Group)... and other collaboratorsUnknown
-
Shanghai Jiao Tong University School of MedicineUnknownCoronary Artery DiseaseChina
-
Paul S Teirstein, MDCordis CorporationCompletedCoronary Artery Disease | Coronary Thrombosis | Coronary RestenosisUnited States
-
Meril Life Sciences Pvt. Ltd.Lifecare Institute of Medical Sciences and Research Ahmedabad Gujarat IndiaCompleted